SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: A meta-analysis found a significant association between the presence of the SLC22A1 variant c.480G>A/C/T (p.Leu160Phe, rs683369) and a lower response rate to imatinib in CML patients[71].